BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some patients continue to have persistant high-grade disease long after treatment, prompting the development of new drugs such as atezolizumab. In this video, Peter Black, MD, of the University of British Colombia, Vancouver, Canada, discusses a clinical trial investigating the efficacy of atezolizumab in BCG-unresponsive bladder cancer (NCT02844816). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.
Can atezolizumab succeed where BCG fails in bladder cancer?
